Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study

In RCT (n=120), pazopanib was noninferior to doxorubicin in terms of progression free survival (HR, 1.00; 95% CI, 0.65 to 1.53) and the incidence of grade 4 neutropenia and febrile neutropenia favoured pazopanib, but overall survival did not differ significantly between arms.

Journal of Clinical Oncology